NO20092584L - Farmasoytiske sammensetninger og deres fremgangsmater for anvendelse - Google Patents
Farmasoytiske sammensetninger og deres fremgangsmater for anvendelseInfo
- Publication number
- NO20092584L NO20092584L NO20092584A NO20092584A NO20092584L NO 20092584 L NO20092584 L NO 20092584L NO 20092584 A NO20092584 A NO 20092584A NO 20092584 A NO20092584 A NO 20092584A NO 20092584 L NO20092584 L NO 20092584L
- Authority
- NO
- Norway
- Prior art keywords
- methods
- pharmaceutical compositions
- composition
- same
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/944—Acetylcholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87460906P | 2006-12-12 | 2006-12-12 | |
US99976107P | 2007-04-12 | 2007-04-12 | |
US11/953,625 US20080167286A1 (en) | 2006-12-12 | 2007-12-10 | Pharmaceutical compositions and their methods of use |
PCT/US2007/087090 WO2008073942A2 (en) | 2006-12-12 | 2007-12-12 | Pharmaceutical compositions and their methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20092584L true NO20092584L (no) | 2009-09-14 |
Family
ID=39427547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20092584A NO20092584L (no) | 2006-12-12 | 2009-07-08 | Farmasoytiske sammensetninger og deres fremgangsmater for anvendelse |
Country Status (16)
Country | Link |
---|---|
US (3) | US20080167286A1 (de) |
EP (3) | EP2226074B1 (de) |
JP (1) | JP2010512419A (de) |
KR (1) | KR20090098884A (de) |
AU (1) | AU2007333129A1 (de) |
BR (1) | BRPI0720124A2 (de) |
CA (1) | CA2671683A1 (de) |
CO (1) | CO6210820A2 (de) |
CR (1) | CR10873A (de) |
DO (1) | DOP2009000137A (de) |
EC (1) | ECSP099495A (de) |
ES (2) | ES2389116T3 (de) |
MX (1) | MX2009006235A (de) |
NO (1) | NO20092584L (de) |
TW (1) | TW200901995A (de) |
WO (1) | WO2008073942A2 (de) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4777663A (en) * | 1986-08-08 | 1988-10-11 | Corning Glass Works | Data rate limiter for optical transmission system |
US7790757B2 (en) | 1998-06-16 | 2010-09-07 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
US8580842B2 (en) | 2003-09-30 | 2013-11-12 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
US7459469B2 (en) | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
IL169855A (en) * | 2005-07-25 | 2014-05-28 | Elta Systems Ltd | A system and method for locating a receiver location |
JP5517453B2 (ja) | 2005-07-26 | 2014-06-11 | ノヴィファーマ,エス.アー. | Comt阻害剤 |
EP1845097A1 (de) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazolderivate als COMT Inihibitoren |
WO2007134038A2 (en) | 2006-05-09 | 2007-11-22 | Astrazeneca Ab | Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine |
TWI389889B (zh) | 2006-05-09 | 2013-03-21 | Targacept Inc | (2s)-(4e)-n-甲基-5-〔3-(5-異丙氧基吡啶)基〕-4-戊烯-2-胺之新穎多晶型 |
US20080167286A1 (en) | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
US8486979B2 (en) | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
US7834039B2 (en) | 2006-12-15 | 2010-11-16 | Abbott Laboratories | Oxadiazole compounds |
UY30846A1 (es) | 2006-12-30 | 2008-07-31 | Abbott Gmbh & Amp | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos |
CA2678391C (en) * | 2007-01-31 | 2017-01-17 | David Alexander Learmonth | Dosage regimen for comt inhibitors |
ES2748599T3 (es) * | 2007-08-27 | 2020-03-17 | Dart Neuroscience Cayman Ltd | Compuestos terapéuticos de isoxazol |
CN101952276B (zh) * | 2007-12-07 | 2014-10-22 | Abbvie德国有限责任两合公司 | 5-卤素取代的羟吲哚衍生物和其用于治疗加压素依赖性疾病的用途 |
JP5701607B2 (ja) * | 2007-12-07 | 2015-04-15 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | アミドメチル置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用 |
WO2010009775A1 (de) * | 2007-12-07 | 2010-01-28 | Abbott Gmbh & Co. Kg | Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen |
EP2623504A1 (de) | 2007-12-07 | 2013-08-07 | Abbott GmbH & Co. KG | 5,6-Disubstituierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen |
RU2010139315A (ru) | 2008-03-17 | 2012-04-27 | Биал - Портела Энд Ка., С.А. (Pt) | Кристаллические формы 5-[3-(2,5-дихлор-4,6-диметил-1-окси-пиридин-3-ил)[1,2,4]оксадиазол-5-ил]-3-нитробензол-1,2-диола |
CA2725573A1 (en) * | 2008-06-06 | 2009-12-10 | Abbott Laboratories | Novel 1,2,4 oxadiazole compounds and methods of use thereof |
EP2344446A4 (de) | 2008-10-17 | 2012-04-04 | Akaal Pharma Pty Ltd | S1p-rezeptormodulatoren |
NZ592748A (en) | 2008-10-17 | 2013-01-25 | Akaal Pharma Pty Ltd | 2-Amino-(oxadiazol-3-yl)-benzofuran derivatives and their use as S1P receptor modulators |
WO2010080757A2 (en) * | 2009-01-07 | 2010-07-15 | Astrazeneca Ab | Combinations with an alpha-4beta-2 nicotinic agonist |
CN102448444B (zh) | 2009-04-01 | 2016-05-25 | 巴尔-波特拉及康邦亚股份有限公司 | 包括硝基儿茶酚衍生物的药物制剂及其制备方法 |
WO2010138600A2 (en) * | 2009-05-29 | 2010-12-02 | Abbott Laboratories | Pharmaceutical compositions for the treatment of pain |
IN2012DN02679A (de) * | 2009-10-12 | 2015-09-04 | Bayer Cropscience Ag | |
US8461171B2 (en) * | 2010-02-09 | 2013-06-11 | QRxPharma Ltd. | Hybrid opioid compounds and compositions |
AU2011256866B2 (en) | 2010-05-20 | 2014-05-22 | Astrazeneca Ab | New process for the preparation of aryl substituted olefinic amines |
US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
CA2823548C (en) * | 2011-09-19 | 2015-10-27 | Suven Life Sciences Limited | Heteroaryl compounds as 5-ht4 receptor ligands |
JP6122858B2 (ja) * | 2011-10-20 | 2017-04-26 | クロモセル コーポレーション | 苦味を調整する化合物を同定するための検定 |
EP3604299B1 (de) | 2011-12-13 | 2023-07-26 | Bial-Portela & CA, S.A. | Chemische verbindung zur verwendung als zwischenprodukt zur herstellung eines catechol-0-methyltransferase-hemmers |
SG11201508572UA (en) | 2013-04-24 | 2015-11-27 | Chromocell Corp | Assays for identifying compounds that modulate bitter taste |
GB2535427A (en) | 2014-11-07 | 2016-08-24 | Nicoventures Holdings Ltd | Solution |
WO2016083863A1 (en) | 2014-11-28 | 2016-06-02 | Bial - Portela & Ca, S.A. | Medicaments for slowing parkinson's disease |
KR102096420B1 (ko) * | 2015-03-31 | 2020-04-02 | 몬산토 테크놀로지 엘엘씨 | 2-싸이오펜카보닐 클로라이드의 제조 방법 |
MX2018011529A (es) | 2016-03-24 | 2019-02-20 | Monsanto Technology Llc | Procesos para la preparacion de acidos heteroaril carboxilicos. |
WO2018187479A1 (en) * | 2017-04-04 | 2018-10-11 | Case Western Reserve University | Method of modulating ribonucleotide reductase |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2950707A (en) | 1959-10-13 | 1960-08-30 | Butler Frank David | Combined liquid fuel and excess air metering and distributing, combined liquid fuel and excess air atomizing and injecting, internal combustion engine |
US3964896A (en) * | 1971-08-09 | 1976-06-22 | Uniroyal, Inc. | Oxadiazole benzoic acid derivatives as herbicides |
US4022901A (en) * | 1975-03-05 | 1977-05-10 | E. R. Squibb & Sons, Inc. | 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles |
CH623971B5 (de) * | 1976-06-04 | 1982-01-15 | Hoechst Ag | Verfahren zur herstellung neuer benzofuranderivate und deren verwendung als optische aufheller. |
JPH07502529A (ja) | 1991-12-31 | 1995-03-16 | 藤沢薬品工業株式会社 | アセチルコリンエステラーゼ阻害およびムスカリン様のアゴニスト活性を有するオキサジアゾール誘導体 |
FR2686878B1 (fr) | 1992-01-30 | 1995-06-30 | Sanofi Elf | Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant. |
US5977144A (en) * | 1992-08-31 | 1999-11-02 | University Of Florida | Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines |
US5948793A (en) * | 1992-10-09 | 1999-09-07 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release |
US5914328A (en) * | 1992-10-09 | 1999-06-22 | Abbott Laboratories | Heterocyclic ether compounds useful in controlling neurotransmitter release |
FR2714378B1 (fr) | 1993-12-24 | 1996-03-15 | Sanofi Sa | Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant. |
IL118279A (en) | 1995-06-07 | 2006-10-05 | Abbott Lab | Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission |
US6130217A (en) * | 1995-09-20 | 2000-10-10 | Pfizer Inc | Compounds enhancing antitumor activity of other cytotoxic agents |
FR2757157B1 (fr) * | 1996-12-13 | 1999-12-31 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant |
WO1999032480A1 (en) | 1997-12-19 | 1999-07-01 | Abbott Laboratories | Heterocyclic ether and thioether compounds useful in controlling chemical synaptic transmission |
US6605610B1 (en) | 1997-12-31 | 2003-08-12 | Pfizer Inc | Aryl fused azapolycyclic compounds |
CA2709735A1 (en) | 1998-06-16 | 1999-12-23 | Targacept, Inc. | Aryl substituted olefinic amines and their use as cholinergic receptors agonists |
US6218383B1 (en) * | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
US6207863B1 (en) | 1998-08-11 | 2001-03-27 | Rohm And Haas Company | Synthesis of haloformimine compounds |
DE19904389A1 (de) | 1999-02-04 | 2000-08-10 | Bayer Ag | Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe |
FR2790474B1 (fr) * | 1999-03-05 | 2001-04-06 | Synthelabo | Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique |
SK16812001A3 (sk) | 1999-05-21 | 2002-05-09 | Abbott Laboratories | Heterocyklické substituované aminoazacykly užitočné ako prostriedky ovplyvňujúce centrálny nervový systém |
US6833370B1 (en) * | 1999-05-21 | 2004-12-21 | Abbott Laboratories | Heterocycle substituted aminoazacycles useful as central nervous system agents |
AU5326100A (en) | 1999-06-07 | 2000-12-28 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
FR2804115B1 (fr) | 2000-01-25 | 2002-03-08 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
FR2804114B1 (fr) | 2000-01-25 | 2002-03-08 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
FR2805536B1 (fr) | 2000-02-25 | 2002-08-23 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
JP2001302643A (ja) | 2000-04-21 | 2001-10-31 | Suntory Ltd | 環状アミジン化合物 |
US6809105B2 (en) * | 2000-04-27 | 2004-10-26 | Abbott Laboratories | Diazabicyclic central nervous system active agents |
MY145722A (en) | 2000-04-27 | 2012-03-30 | Abbott Lab | Diazabicyclic central nervous system active agents |
US6448288B1 (en) | 2000-05-17 | 2002-09-10 | University Of Massachusetts | Cannabinoid drugs |
US6579880B2 (en) * | 2000-06-06 | 2003-06-17 | Ortho-Mcneil Pharmaceutical, Inc. | Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8 |
FR2810320B1 (fr) * | 2000-06-19 | 2002-08-23 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
KR100838447B1 (ko) | 2001-02-21 | 2008-06-16 | 아스트라제네카 아베 | 헤테로폴리시클릭 화합물 및 대사향성 글루타메이트수용체 길항제로서의 그의 용도 |
MXPA03011196A (es) * | 2001-06-08 | 2004-10-28 | Cytovia Inc | 3-aril-5-aril-[1,2,4]-oxadiazoles sustituidos y analogos. |
FR2827604B1 (fr) | 2001-07-17 | 2003-09-19 | Sanofi Synthelabo | Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
BR0214031A (pt) * | 2001-11-08 | 2004-10-19 | Upjohn Co | Compostos de heteroarila azabicìclico substituìdos para o tratamento de doenças |
US7135484B2 (en) * | 2002-08-14 | 2006-11-14 | Abbott Laboratories | Azabicyclic compounds are central nervous system active agents |
WO2004018607A2 (en) | 2002-08-20 | 2004-03-04 | The Procter & Gamble Company | Method for maufacturing liquid gel automatic dishwashing detergent compositions comprising anhydrous solvent |
HUE059464T2 (hu) * | 2003-04-11 | 2022-11-28 | Ptc Therapeutics Inc | 1,2,4-Oxadiazolbenzoesav-vegyületek és ezek alkalmazása nonsense szuppresszióhoz és betegségek kezelésére |
US20050070718A1 (en) | 2003-09-30 | 2005-03-31 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
US8580842B2 (en) | 2003-09-30 | 2013-11-12 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
WO2005034952A2 (en) * | 2003-10-07 | 2005-04-21 | The Feinstein Institute For Medical Research | Isoxazole and isothiazole compounds useful in the treatment of inflammation |
DE102004033834A1 (de) | 2004-07-13 | 2006-02-02 | Abbott Gmbh & Co. Kg | Substituierte Oxindol-Derivate und diese enthaltende Arzneimittel |
WO2006019832A1 (en) * | 2004-07-22 | 2006-02-23 | Ptc Therapeutics, Inc. | Thienopyridines for treating hepatitis c |
WO2006047392A2 (en) * | 2004-10-21 | 2006-05-04 | The Trustees Of Columbia University In The City Of New York | Nicotinic-opioid synergy for analgesia |
US8378109B2 (en) * | 2004-12-07 | 2013-02-19 | The Regents Of The University Of California | Labeled ALPHA4BETA2 ligands and methods therefor |
JP2008525524A (ja) | 2004-12-28 | 2008-07-17 | アストラゼネカ・アクチエボラーグ | アリールスルホンアミドモジュレーター |
US20120115842A1 (en) | 2004-12-31 | 2012-05-10 | Wilfried Lubisch | Substituted Oxindole Derivatives, Medicaments Containing Said Derivatives and Use Thereof |
WO2006080574A1 (ja) * | 2005-01-28 | 2006-08-03 | Taisho Pharmaceutical Co., Ltd. | 1,3-ジヒドロ-2h-インドール-2-オン化合物、及び芳香族複素環が縮合したピロリジン-2-オン化合物 |
US7019503B1 (en) | 2005-02-07 | 2006-03-28 | Raytheon Company | Active power filter with input voltage feedforward, output load feedforward, and output voltage feedforward |
US20080261999A1 (en) * | 2005-03-04 | 2008-10-23 | Fionna Mitchell Martin | Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists |
DE102005014936A1 (de) * | 2005-03-24 | 2006-12-14 | Abbott Gmbh & Co. Kg | Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung |
DE102005014904A1 (de) * | 2005-03-26 | 2007-02-01 | Abbott Gmbh & Co. Kg | Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung |
JP2008534461A (ja) | 2005-03-24 | 2008-08-28 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 置換オキシインドール誘導体、前記誘導体を含む医薬およびそれの使用 |
CA2606087A1 (en) * | 2005-04-26 | 2006-11-02 | Neurosearch A/S | Novel oxadiazole derivatives and their medical use |
US20070184490A1 (en) * | 2006-01-17 | 2007-08-09 | Marleen Verlinden | Neuronal nicotinic receptor ligands and their use |
WO2007149395A2 (en) | 2006-06-20 | 2007-12-27 | Amphora Discovery Corporation | 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer |
WO2008028903A2 (en) | 2006-09-04 | 2008-03-13 | Neurosearch A/S | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
US20080167286A1 (en) | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
US8486979B2 (en) * | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
UY30846A1 (es) * | 2006-12-30 | 2008-07-31 | Abbott Gmbh & Amp | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos |
WO2008080970A1 (en) | 2006-12-30 | 2008-07-10 | Abbott Gmbh & Co. Kg | Substituted oxindole derivative and its use as a vasopressin receptor ligand |
WO2008080971A1 (en) | 2006-12-30 | 2008-07-10 | Abbott Gmbh & Co. Kg | Substituted oxindole derivative and its use as a vasopressin receptor ligand |
EP2114922B1 (de) | 2006-12-30 | 2013-04-24 | Abbott GmbH & Co. KG | Substituiertes oxindolderivat und dessen verwendung als vasopressinrezeptormodulator |
US20080255203A1 (en) * | 2007-04-12 | 2008-10-16 | Abbott Laboratories | Heterocyclic compounds and their methods of use |
JP5701607B2 (ja) | 2007-12-07 | 2015-04-15 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | アミドメチル置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用 |
CN101952276B (zh) | 2007-12-07 | 2014-10-22 | Abbvie德国有限责任两合公司 | 5-卤素取代的羟吲哚衍生物和其用于治疗加压素依赖性疾病的用途 |
WO2010009775A1 (de) | 2007-12-07 | 2010-01-28 | Abbott Gmbh & Co. Kg | Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen |
EP2623504A1 (de) | 2007-12-07 | 2013-08-07 | Abbott GmbH & Co. KG | 5,6-Disubstituierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen |
CA2725573A1 (en) | 2008-06-06 | 2009-12-10 | Abbott Laboratories | Novel 1,2,4 oxadiazole compounds and methods of use thereof |
WO2010138600A2 (en) | 2009-05-29 | 2010-12-02 | Abbott Laboratories | Pharmaceutical compositions for the treatment of pain |
CN101730041A (zh) | 2009-06-26 | 2010-06-09 | 中兴通讯股份有限公司 | 一种基于用户当前所在时区的策略和计费控制方法及系统 |
US8815858B2 (en) | 2010-05-21 | 2014-08-26 | Gilead Sciences, Inc. | Heterocyclic flaviviridae virus inhibitors |
-
2007
- 2007-12-10 US US11/953,625 patent/US20080167286A1/en not_active Abandoned
- 2007-12-12 EP EP10163998.7A patent/EP2226074B1/de active Active
- 2007-12-12 JP JP2009541533A patent/JP2010512419A/ja active Pending
- 2007-12-12 ES ES07869109T patent/ES2389116T3/es active Active
- 2007-12-12 TW TW096147575A patent/TW200901995A/zh unknown
- 2007-12-12 MX MX2009006235A patent/MX2009006235A/es not_active Application Discontinuation
- 2007-12-12 BR BRPI0720124-9A2A patent/BRPI0720124A2/pt not_active IP Right Cessation
- 2007-12-12 AU AU2007333129A patent/AU2007333129A1/en not_active Abandoned
- 2007-12-12 ES ES10163998.7T patent/ES2558054T3/es active Active
- 2007-12-12 EP EP15180552.0A patent/EP2974727A1/de not_active Withdrawn
- 2007-12-12 CA CA002671683A patent/CA2671683A1/en not_active Abandoned
- 2007-12-12 EP EP07869109A patent/EP2101763B1/de active Active
- 2007-12-12 WO PCT/US2007/087090 patent/WO2008073942A2/en active Application Filing
- 2007-12-12 KR KR1020097014515A patent/KR20090098884A/ko not_active Application Discontinuation
-
2009
- 2009-06-09 DO DO2009000137A patent/DOP2009000137A/es unknown
- 2009-06-19 CR CR10873A patent/CR10873A/es unknown
- 2009-06-26 CO CO09066751A patent/CO6210820A2/es not_active Application Discontinuation
- 2009-07-07 EC EC2009009495A patent/ECSP099495A/es unknown
- 2009-07-08 NO NO20092584A patent/NO20092584L/no not_active Application Discontinuation
-
2011
- 2011-04-05 US US13/080,071 patent/US9186407B2/en not_active Expired - Fee Related
-
2015
- 2015-10-07 US US14/877,783 patent/US20160022658A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ECSP099495A (es) | 2009-08-28 |
TW200901995A (en) | 2009-01-16 |
JP2010512419A (ja) | 2010-04-22 |
AU2007333129A1 (en) | 2008-06-19 |
US20160022658A1 (en) | 2016-01-28 |
CR10873A (es) | 2009-07-23 |
US20080167286A1 (en) | 2008-07-10 |
ES2389116T3 (es) | 2012-10-23 |
BRPI0720124A2 (pt) | 2014-03-04 |
DOP2009000137A (es) | 2009-06-30 |
MX2009006235A (es) | 2009-06-22 |
WO2008073942A3 (en) | 2008-12-04 |
EP2101763B1 (de) | 2012-07-18 |
EP2226074A2 (de) | 2010-09-08 |
CA2671683A1 (en) | 2008-06-19 |
EP2226074B1 (de) | 2015-11-04 |
KR20090098884A (ko) | 2009-09-17 |
EP2101763A2 (de) | 2009-09-23 |
CO6210820A2 (es) | 2010-10-20 |
US9186407B2 (en) | 2015-11-17 |
WO2008073942A2 (en) | 2008-06-19 |
EP2974727A1 (de) | 2016-01-20 |
US20110190314A1 (en) | 2011-08-04 |
ES2558054T3 (es) | 2016-02-01 |
EP2226074A3 (de) | 2011-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20092584L (no) | Farmasoytiske sammensetninger og deres fremgangsmater for anvendelse | |
NO20090175L (no) | Stabile laquinimod sammensetninger | |
EA200900023A1 (ru) | Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли | |
EA200870193A1 (ru) | Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение | |
CY1111729T1 (el) | Υπογλωσσιο επικαλυμμενο δισκιο | |
NO20064041L (no) | Substituerte pyrazolin sammensetninger, deres fremstilling og anvendelse som medikamenter | |
NO20092611L (no) | Krystallinsk faststoff Rasagilin base | |
NO20064325L (no) | Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes | |
DK3072507T3 (da) | Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi | |
UA96308C2 (ru) | Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение | |
NO20074823L (no) | Rasagilin-formuleringer med forbedret innholdsensartethet | |
DK2024352T3 (da) | Glucopyranosylsubstituerede benzoenitrilderivater, farmaceutiske sammensætninger indeholdende sådanne forbindelser, deres anvendelse og fremgangsmåde for deres fremstilling | |
NO20090157L (no) | Tienpyrimidiner anvendelige som modulatorer av ionekanaler | |
ATE430744T1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren | |
WO2007146965A3 (en) | Compounds for the treatment of periodontal disease | |
IL205360A0 (en) | Methods, kits, and compositions for administering pharmaceutical compounds | |
EA200800665A1 (ru) | АГЕНТЫ ДЛЯ ПРЕДУПРЕЖДЕНИЯ И ЛЕЧЕНИЯ НАРУШЕНИЙ, ВКЛЮЧАЮЩИХ МОДУЛИРОВАНИЯ RyR РЕЦЕПТОРОВ | |
NO20083057L (no) | Sulfonyl substituerte 1H-indoler som ligander til 5-hydroksytryptamin reseptorer | |
NO20084850L (no) | MGLUR5 modulatorer I | |
NO20084852L (no) | MGLUR5 modulatorer V | |
NO20083584L (no) | Bensoyl-piperidin derivater som 5HT2/D3 modulatorer | |
NO20084826L (no) | Ny administrasjonsform av racecadotril | |
UA93709C2 (ru) | 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций | |
MX2010006206A (es) | Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
DE602006018713D1 (de) | Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |